EUVIMEDEUVIMED entdecken
Crossref

Enzyme−Antibiotic Liquid Crystalline Nanoparticles for Enhanced Antibiofilm Activity, Bacterial Clearance, and Accelerated Healing of Infected Wounds

Anam Ahsan, Hang Thi Nguyen, Anthony Wignall, Zlatko Kopecki, Timothy J Barnes iD, Nicky Thomas, Abiodun David Ogunniyi, Clive A Prestidge iD

ACS Applied Materials & Interfaces · 11.11.2026 · 18 (44) · 60428-60448

DOI: 10.1021/acsami.6c13295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 03.11.2026. Verfasst von Anam Ahsan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Innovation, School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA5000, Australia. Hauptthemen laut MEDLINE: Biofilms, Anti-Bacterial Agents, Escherichia coli, Nanoparticles. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biofilm-associated wound infections remain difficult to treat because bacteria are protected within extracellular polymeric matrices that restrict antibiotic penetration, promote antimicrobial tolerance, and delay tissue repair. Here, we developed liquid crystalline nanoparticles (LCNPs) for topical coformulation of gentamicin (GEN) and recombinant human DNase I (rhDNase), combining aminoglycoside therapy with an eDNA-targeting enzyme. GEN + rhDNase-LCNPs were successfully formulated as nanoscale particles with low polydispersity, high encapsulation efficiency, and formulation-dependent in vitro release behavior. LCNP formulation preserved GEN antibacterial activity against planktonic Escherichia coli Xen14 and reduced the MBIC against established biofilms by approximately 4-fold. In a minimum biofilm eradication concentration (MBEC) model, GEN + rhDNase-LCNPs achieved the greatest reduction in biofilm-associated viable bacteria, producing an approximately 6-log reduction compared with untreated biofilm controls and supporting the benefit of combining antibiotic delivery with rhDNase. Notably, GEN + rhDNase-LCNPs markedly suppressed bacterial burden and reduced recoverable bacteria at day 9 to near the limit of detection in a bioluminescent E. coli Xen14 biofilm-associated excisional wound infection mouse model. This antibacterial effect translated into accelerated macroscopic wound closure and improved histological repair, including an approximately 80% reduction in wound gape compared with infected controls. Masson’s trichrome staining further confirmed enhanced tissue remodeling, with the collagen-positive wound area increasing to approximately 88% following GEN + rhDNase-LCNP treatment, compared with approximately 21% in infected controls. In conclusion, LCNP-mediated codelivery of GEN and rhDNase improved bacterial clearance, re-epithelialization, and collagen deposition, supporting this platform as a promising topical antibiofilm strategy for infected wounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiofilmsAnti-Bacterial AgentsEscherichia coliNanoparticlesWound HealingDeoxyribonuclease IWound InfectionGentamicinsAnimalsMiceHumansMicrobial Sensitivity TestsRecombinant Proteins

Stichwörter der Autor:innen

E. coliGENaccelerated healingchronic woundshemocompatibilitylCNPsrhDNase

Substanzen

Anti-Bacterial AgentsDeoxyribonuclease IGentamicinsRecombinant Proteins

Autor:innen und Institutionen

  • Centre for Pharmaceutical Innovation, School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA5000, Australia.
  • Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, College of Science, Adelaide University, Roseworthy, SA5371, Australia.
  • ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance, The University of Queensland, Brisbane, QLD4072, Australia.
  • Future Industries Institute, Adelaide University, Mawson Lakes, SA5095, Australia.
  • PolyNovo Biomaterials Pty Ltd , Unit 2/320 Lorimer Street, Port Melbourne, VIC3207, Australia.
  • Global Iodine Solutions Ltd, 1002 Hay Street, Perth, WA6000, Australia.

ORCID-Profile: Timothy J Barnes, Clive A Prestidge

Zitieren

APA

Ahsan, A., Nguyen, H. T., Wignall, A., Kopecki, Z., Barnes, T. J., Thomas, N., Ogunniyi, A. D., & Prestidge, C. A. (2026). Enzyme−Antibiotic Liquid Crystalline Nanoparticles for Enhanced Antibiofilm Activity, Bacterial Clearance, and Accelerated Healing of Infected Wounds. ACS Applied Materials & Interfaces, 18(44), 60428-60448. https://doi.org/10.1021/acsami.6c13295

Vancouver

Ahsan A, Nguyen HT, Wignall A, Kopecki Z, Barnes TJ, Thomas N, et al. Enzyme−Antibiotic Liquid Crystalline Nanoparticles for Enhanced Antibiofilm Activity, Bacterial Clearance, and Accelerated Healing of Infected Wounds. ACS Applied Materials & Interfaces. 2026;18(44):60428-60448. doi:10.1021/acsami.6c13295

BibTeX
@article{Ahsan2026,
  author = {Ahsan, Anam and Nguyen, Hang Thi and Wignall, Anthony and Kopecki, Zlatko and Barnes, Timothy J and Thomas, Nicky and Ogunniyi, Abiodun David and Prestidge, Clive A},
  title = {Enzyme−Antibiotic Liquid Crystalline Nanoparticles for Enhanced Antibiofilm Activity, Bacterial Clearance, and Accelerated Healing of Infected Wounds},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  volume = {18},
  number = {44},
  pages = {60428--60448},
  doi = {10.1021/acsami.6c13295}
}
Kostenlos starten →